Antibody-drug Conjugate Technology Collaborations

Seattle Genetics has entered into multiple collaborations for its antibody-drug conjugate (ADC) technology with industry-leading biotechnology and pharmaceutical companies. There are currently 12 collaborator ADC programs in clinical development utilizing Seattle Genetics' technology. We have two types of ongoing ADC collaborations:

ADC License Agreements
Under our ADC license agreements with Abbott, Agensys, Bayer, Celldex, Daiichi-Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, Seattle Genetics is entitled to receive upfront payments, milestones and royalties on net sales of any resulting ADC products. We have the potential to receive more than $3 billion in future milestone payments across our ADC collaborations. Our licensees are responsible for all development, manufacturing and commercialization activities under these collaborations.

ADC Co-Development Agreements
Our ADC co-development agreements with Agensys and Genmab provide Seattle Genetics with opportunities to supplement our internal pipeline through opt-in rights to 50:50 co-development and profit-sharing for ADC product candidates. Under our Agensys deal, we are co-developing ASG-5ME and ASG-22ME and have an opt-in right to one additional ADC program upon IND submission. Through our Genmab deal, we have opt-in rights to two ADC programs at completion of phase I clinical trials. Under both deals, if we do not opt-in, we are entitled to receive milestones and royalties on net sales of any resulting ADC products.

ADC COLLABORATOR PIPELINE